AR119021A1 - Composiciones de acetato de leuprolida y métodos de uso de estas para tratar el cáncer de mama - Google Patents

Composiciones de acetato de leuprolida y métodos de uso de estas para tratar el cáncer de mama

Info

Publication number
AR119021A1
AR119021A1 ARP200101496A ARP200101496A AR119021A1 AR 119021 A1 AR119021 A1 AR 119021A1 AR P200101496 A ARP200101496 A AR P200101496A AR P200101496 A ARP200101496 A AR P200101496A AR 119021 A1 AR119021 A1 AR 119021A1
Authority
AR
Argentina
Prior art keywords
sustained release
release composition
biodegradable polymer
breast cancer
methods
Prior art date
Application number
ARP200101496A
Other languages
English (en)
Spanish (es)
Inventor
John Middleton
Avinash Nangia
John Arthur Mlane
Terri L Morton
Original Assignee
Tolmar International Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tolmar International Ltd filed Critical Tolmar International Ltd
Publication of AR119021A1 publication Critical patent/AR119021A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/566—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Reproductive Health (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Peptides Or Proteins (AREA)
ARP200101496A 2019-05-27 2020-05-27 Composiciones de acetato de leuprolida y métodos de uso de estas para tratar el cáncer de mama AR119021A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962853153P 2019-05-27 2019-05-27

Publications (1)

Publication Number Publication Date
AR119021A1 true AR119021A1 (es) 2021-11-17

Family

ID=70922081

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP200101496A AR119021A1 (es) 2019-05-27 2020-05-27 Composiciones de acetato de leuprolida y métodos de uso de estas para tratar el cáncer de mama

Country Status (17)

Country Link
US (2) US12453754B2 (cg-RX-API-DMAC7.html)
EP (1) EP3975990A1 (cg-RX-API-DMAC7.html)
JP (1) JP7664855B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220041782A (cg-RX-API-DMAC7.html)
CN (1) CN114144169A (cg-RX-API-DMAC7.html)
AR (1) AR119021A1 (cg-RX-API-DMAC7.html)
AU (1) AU2020284587B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021023904A2 (cg-RX-API-DMAC7.html)
CA (1) CA3141456A1 (cg-RX-API-DMAC7.html)
EA (1) EA202193257A1 (cg-RX-API-DMAC7.html)
IL (1) IL288503A (cg-RX-API-DMAC7.html)
MX (1) MX2021014540A (cg-RX-API-DMAC7.html)
PH (1) PH12021552976A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202112888RA (cg-RX-API-DMAC7.html)
TW (1) TWI757753B (cg-RX-API-DMAC7.html)
UY (1) UY38717A (cg-RX-API-DMAC7.html)
WO (1) WO2020240417A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202112888RA (en) 2019-05-27 2021-12-30 Tolmar International Ltd Leuprolide acetate compositions and methods of using the same to treat breast cancer
KR102742097B1 (ko) 2020-12-23 2024-12-11 톨마 인터내셔날 리미티드 혼합 주사기 밸브 어셈블리를 위한 시스템 및 방법
CN115518144A (zh) * 2021-06-26 2022-12-27 王婧宜 一种含有亮丙瑞林或其衍生物的口服药物组合物
USD1029245S1 (en) 2022-06-22 2024-05-28 Tolmar International Limited Syringe connector

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4938763B1 (en) 1988-10-03 1995-07-04 Atrix Lab Inc Biodegradable in-situ forming implants and method of producing the same
US5702716A (en) 1988-10-03 1997-12-30 Atrix Laboratories, Inc. Polymeric compositions useful as controlled release implants
US5324519A (en) 1989-07-24 1994-06-28 Atrix Laboratories, Inc. Biodegradable polymer composition
EP1125577B1 (en) 1994-04-08 2006-02-15 QLT USA, Inc. Liquid drug delivery compositions
US6565874B1 (en) 1998-10-28 2003-05-20 Atrix Laboratories Polymeric delivery formulations of leuprolide with improved efficacy
US8470359B2 (en) 2000-11-13 2013-06-25 Qlt Usa, Inc. Sustained release polymer
CA2637569C (en) * 2006-01-18 2013-01-08 Yuhua Li Pharmaceutical compositions with enhanced stability
EP3202814B1 (en) * 2007-02-15 2019-10-16 Tolmar Therapeutics, Inc. Low burst poly-(lactide/glycolide) and methods to produce polymers
DE202009010095U1 (de) 2009-07-24 2009-10-22 Chang, Ti-Li, Houli Verbindungsvorrichtung für einen auswechselbaren, abgeschlossenen Sekret-Absaugkatheter
HUE044352T2 (hu) * 2011-10-14 2019-10-28 Hoffmann La Roche Pertuzumab, Trastuzumab, Docetaxel és Carboplatin korai stádiumú mellrák kezelésére
SG11202112888RA (en) 2019-05-27 2021-12-30 Tolmar International Ltd Leuprolide acetate compositions and methods of using the same to treat breast cancer
KR102162217B1 (ko) 2020-05-07 2020-10-06 주식회사 파인비엠 스태틱믹서를 갖는 연결장치를 구비한 시린지 결합 키트
KR102742097B1 (ko) 2020-12-23 2024-12-11 톨마 인터내셔날 리미티드 혼합 주사기 밸브 어셈블리를 위한 시스템 및 방법
AU2022331238A1 (en) 2021-08-19 2024-02-01 Carefusion 303, Inc. Pivc-integrated hemolysis-reduction accessories with anti-spillage component for direct blood draw
FR3131618A1 (fr) 2021-12-30 2023-07-07 Parker Hannifin Emea Sarl Dispositif de raccordement aseptique d’un tube

Also Published As

Publication number Publication date
IL288503A (en) 2022-01-01
US20220265760A1 (en) 2022-08-25
AU2020284587B2 (en) 2025-09-18
CN114144169A (zh) 2022-03-04
US20260027176A1 (en) 2026-01-29
KR20220041782A (ko) 2022-04-01
US12453754B2 (en) 2025-10-28
PH12021552976A1 (en) 2022-07-04
UY38717A (es) 2020-11-30
TWI757753B (zh) 2022-03-11
TW202110472A (zh) 2021-03-16
SG11202112888RA (en) 2021-12-30
JP2022535694A (ja) 2022-08-10
MX2021014540A (es) 2022-04-12
BR112021023904A2 (pt) 2022-02-01
JP7664855B2 (ja) 2025-04-18
WO2020240417A1 (en) 2020-12-03
CA3141456A1 (en) 2020-12-03
AU2020284587A1 (en) 2022-01-06
EP3975990A1 (en) 2022-04-06
EA202193257A1 (ru) 2022-03-10

Similar Documents

Publication Publication Date Title
AU2020250230B2 (en) Compositions of a polyorthoester and an aprotic solvent
US10646572B2 (en) Pharmaceutical compositions with enhanced stability
ES2600797T3 (es) Composiciones farmacéuticas
US20150150987A1 (en) Biodegradable drug delivery for hydrophobic compositions
TWI805558B (zh) 混合物與配方
CY1109425T1 (el) Φαρμακευτικες συνθεσεις για τη χορηγηση με ελεγχομενη αποδεσμευση βιολογικα δραστικων ενωσεων
IL282551B1 (en) Antiviral prodrugs and their nanoformulations
WO2003034988A3 (en) Injectable compositions for the controlled delivery of pharmacologically active compound
RU2011136636A (ru) Фармацевтическая композиция для орального введения
RU2011105029A (ru) Доставка октреотида из сухих лекарственных форм
MX2022000489A (es) Formulacion de larga duracion que contiene rivastigmina y metodo para prepararla.
RU2017110076A (ru) Фармацевтическая композиция и способы
AR118753A1 (es) Método de tratamiento de un niño con pubertad precoz central usando una composición de liberación prolongada
AR098389A1 (es) Complejos de fulvestrant y sus derivados, proceso para su preparación y composiciones farmacéuticas que los contienen
JP2022541452A (ja) がんの治療のための方法および組成物
CN111511385B (zh) 具有选定的释放持续时间的药物组合物
Koffi et al. In vitro and in vivo characteristics of a thermogelling and bioadhesive delivery system intended for rectal administration of quinine in children
SE9603480L (sv) Beredningsform för svårlösliga läkemedel
Yang et al. Molecular design of hyaluronic acid hydrogel networks for long-term controlled delivery of human growth hormone
WO2004091541A3 (en) Methods for the controlled delivery of pharmacologically active compounds
Wüthrich et al. Effect of formulation additives upon the intranasal bioavailability of a peptide drug: Tetracosactide (ACTH1− 24)
Masoumzadeh et al. Development of polymeric micelles loaded with STAT3 inhibitory, stattic, for cancer treatment
Lokesh et al. Enhanced cytotoxic effect of chemically conjugated polymeric sirolimus against ht-29 colon cancer and a-549 lung cancer cell lines
WO2025085869A1 (en) Improved hydrogel for delivery of pharmaceutical agents

Legal Events

Date Code Title Description
FA Abandonment or withdrawal